An overall picture of SARS coronavirus (SARS-CoV) genome-encoded major proteins: structures, functions and drug development.
A severe atypical pneumonia designated as severe acute respiratory syndrome (SARS) by The World Health Organization broke out in China and menaced to more than other 30 countries between the end of the year 2002 and June of the year 2003. A novel coronavirus called severe acute respiratory syndrome coronavirus (SARS-CoV) has been recently identified as the etiological agent responsible for the infectious SARS disease. Based on extensively scientific cooperation and almost two-year's studies, remarkable achievements have been made in the understanding of the phylogenetic property and the genome organization of SARS-CoV, as well as the detailed characters of the major proteins involved in SARS-CoV life cycle. In this review, we would like to summarize the substantial scientific progress that has been made towards the structural and functional aspects of SARS-CoV associated key proteins. The progress focused on the corresponding key proteins' structure-based drug and vaccine developments has been also highlighted. The concerted and cooperative response for the treatment of the SARS disease has been proved to be a triumph of global public health and provides a new paradigm for the detection and control of future emerging infectious disease threats.
Chen
Shuai
S
Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 201203, China.
Luo
Haibin
H
Chen
Lili
L
Chen
Jing
J
Shen
Jianhua
J
Zhu
Weiliang
W
Chen
Kaixian
K
Shen
Xu
X
Jiang
Hualiang
H
D000998:Antiviral Agents / Q000494:pharmacology*; D000086782:Coronavirus 3C Proteases; D000086862:Coronavirus M Proteins; D000086462:Coronavirus Nucleocapsid Proteins; D003546:Cysteine Endopeptidases / Q000737:chemistry / Q000378:metabolism; D015195:Drug Design; D016679:Genome, Viral; D008562:Membrane Glycoproteins / Q000737:chemistry / Q000378:metabolism; D008958:Models, Molecular; D019590:Nucleocapsid Proteins / Q000737:chemistry / Q000378:metabolism; D011487:Protein Conformation; D045473:Severe acute respiratory syndrome-related coronavirus / Q000187:drug effects / Q000235:genetics*; D064370:Spike Glycoprotein, Coronavirus; D014759:Viral Envelope Proteins / Q000737:chemistry / Q000378:metabolism; D014763:Viral Matrix Proteins / Q000737:chemistry / Q000378:metabolism; D017361:Viral Nonstructural Proteins / Q000737:chemistry / Q000378:metabolism; D014764:Viral Proteins / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D014765:Viral Vaccines; D000086082:Viroporin Proteins
D000998:Antiviral Agents; D000086862:Coronavirus M Proteins; D000086462:Coronavirus Nucleocapsid Proteins; C501689:E protein, SARS coronavirus; C000706237:M protein, SARS-CoV; D008562:Membrane Glycoproteins; D019590:Nucleocapsid Proteins; D064370:Spike Glycoprotein, Coronavirus; D014759:Viral Envelope Proteins; D014763:Viral Matrix Proteins; D017361:Viral Nonstructural Proteins; D014764:Viral Proteins; D014765:Viral Vaccines; D000086082:Viroporin Proteins; C578557:spike glycoprotein, SARS-CoV; D003546:Cysteine Endopeptidases; D000086782:Coronavirus 3C Proteases